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individuals caring for visually impaired patients remains unknown. The study objec-
tive is to outlook the instruments currently available for measuring caregiver burden 
for visually impaired patients and to identify whether linguistic validation has been 
done in Japan. Methods: We performed a literature review on articles describing 
instruments of caregiver reported outcomes for eye disorders. We summarized the 
current evidence on the usefulness of the instruments and whether they differentiate 
between eye diseases and other non-eye related diseases. In addition, we investigated 
possible hurdles in measuring caregiver burden in eye disorders, given the environ-
mental understandings of patients with visual impairments and their caregivers in 
Japan. Results: We identified two caregiver burden measurements, one depression 
measurement, and one life-satisfaction scale used in studies for measuring caregiver 
outcome for patients with visual impairments. A few studies using these instruments 
demonstrated correlation between the degree of caregiver burden and/or level of 
depression and severity of visual impairments. Excluding one caregiver burden instru-
ment, Japanese versions of the remaining three instruments have been developed and 
validated. However, realistic use of these instruments are still questionable because: 
1) most of the patients with visual impairments in Japan are elderly and increased 
caregiver burden may be due to conditions associated with older age, and 2) aging 
of caregivers are also progressing, resulting in increased perceived caregiver burden 
to support the patients. ConClusions: Evidence is limited when measuring the 
impacts of eye diseases on their caregivers. Further research is required to identify 
the usefulness of these instruments to measure caregiver burden for patients with 
eye diseases in Japan.
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DeveloPMent of electRonic DiaRy in Patients With PRiMaRy BiliaRy 
ciRRhosis
Gilchrist K., Vallow S.
GlaxoSmithKline, King of Prussia, PA, USA
objeCtives: Primary biliary cirrhosis (PBC) is a disease with chronic symptoms such 
as fatigue and itching. To characterize the varied symptoms of PBC and evaluate ben-
efits of new PBC treatments, an electronic diary (e-diary) was developed. Methods: 
E-diary items were developed based on PBC-40 (health related questionnaire devel-
oped for PBC), other pruritis questionnaires and clinical consult. Concept elicita-
tion interviews were conducted with PBC patients from the UK to further confirm 
PBC symptoms, symptom characteristics, impact and relevance. PBC patients with 
ongoing or previous (< 2 years) symptoms participated. Cognitive debriefing of the 
diary was conducted with the e-diary format and confirmed usability. In addition, the 
interview evaluated the PBC-40 as 4 week recall period to determine feasibility of 1 
week recall. Results: 10 PBC subjects participated mean age 54.1, +12.9 years; 9/10 
subjects were women. Subjects commonly reported experiencing itch, fatigue, and 
impacts on sleep, confirming importance for inclusion in the e-diary. Frequency of 
itch and fatigue also varied, supporting frequent capture. Subjects reported e-diaries 
were relevant, appropriate and could be easily used for symptom reporting. Interviews 
focusing on PBC-40 recall period supported the change from “past 4 weeks” to “past 1 
week.” ConClusions: Capture of PBC symptoms such as itch and other symptoms 
of PBC that vary frequently in an e-diary, and usability of the e-diary, was supported 
through interviews with PBC patients. Symptom characterization of itching could be 
further refined. Funding for this study was provided by GlaxoSmithKline
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Patients tReateD With insulin in tWo coloMBian cities
Medina Morales D.A., Machado Alba J.E., Echeverry-Cataño L.F., Londoño-Builes M.J.
Universidad Tecnológica de Pereira, Pereira, Colombia
objeCtives: Diabetes mellitus is a public health problem and its influence is rec-
ognized in the quality of life of patients. According to WHO, only 50% of people have 
adherence to treatment of chronic diseases. This study evaluated and compared 
the results of the scales measuring quality of life and adherence to treatment in 
two groups of patients with diabetes and treatment with conventional or analogue 
insulins Methods: Cross-sectional study in two groups of patients diagnosed 
with diabetes mellitus type 1 or type 2, in medical treatment with conventional or 
analogues insulines, for at least six months in two cities in Colombia. The sample 
was calculated with a ratio of 0.5-Control Group, with estimated RR of 0.75 and 
allocation rate between groups of 0.5. Each patient responded two scales measuring 
quality of life (EQ-5D and Diabetes-39) and two scales measuring adherence (Morisky 
Green and Medication Possession Ratio) and comparison was made between the 
results obtained. Results: 240 patients with a mean age of 57.7 ± 16.6 years were 
included, 69.6% were prescribed whit conventional insulin and 30.4% with ana-
logues insulin. 68.3% of patients were adherent to medical therapy and only 7.1% 
(n = 17) had high quality of life. Patients more than 60 years were less likely to have 
high quality of life (OR: 0.177; 95% CI 0.050 to 0.635; p = 0.003), while adherence 
was less likely in patients aged 31-45 years (OR: 0.427; 95% CI 0.187 to 0.971; p = 
0.038). ConClusions: The quality of life and treatment adherence is significantly 
affected in patients with diabetes mellitus, which may also impact its metabolic 
control. It is necessary to establish individual and group interventions to improve 
these conditions in patients.
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objeCtives: The Irritable Bowel Syndrome Quality of Life Instrument (IBS-QOL) 
is a self-report measure developed to assess the impact of IBS and its treatment. 
The instrument contains 34 items, rated on a five-point scale. The IBS-QOL was 
were noted. In addition the 2011 South African Census was reviewed. Results: The 
2011 census revealed, of 11 official languages, English is the most common ‘everyday’ 
language in business, politics and the media. However, it’s not the most common lan-
guage spoken at home. This inconsistency causes translation issues for the following 
reasons: (1) English names are commonly used for diseases and drugs, as these are 
referred to in ‘home’ languages with varying localised terms/descriptions (2) There 
is not the same broad vocabulary in the ‘home’ languages, due to the prevalence 
of English outside of the home, so descriptions are often used to reflect the source 
wording (3) Attitudes towards biomedicine can be subject to cultural differences in 
South Africa so certain concepts have to be localised and may appear to differ sig-
nificantly from the source (4) ‘Home’ languages are not often written so have evolved 
erratically, with different linguists having different opinions on spelling and gram-
mar ConClusions: This distinction between the ‘everyday’ language used in work, 
education, etc. and the ‘home’ languages causes difficulties with linguistic validation 
for South Africa. Linguists disagree on the general use of the languages which seems 
to be constantly changing. However, while the translation issues are multiple and 
varied the linguistic validation process appears to provide the resolutions, where all 
source wording is translated, reviewed, questioned and discussed in order to find a 
conceptual equivalent rather than a literal translation.
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RecoMMenDations foR the linguistic valiDation of PeDiatRic 
clinical outcoMes assessMents
Gawlicki M.1, Brandt B.1, McKown S.1, Talbert M.2
1Corporate Translations Inc, East Hartford, CT, USA, 2Corporate Translations Inc, Chicago, IL, USA
objeCtives: The objective of this study was to test cognitive debriefing strategies 
for translated Clinical Outcomes Assessments (COA) intended for pediatric popula-
tions. Methods: Two questionnaires were translated into 11 languages, each for a 
specific pediatric population. One was an assessment on the palatability of medi-
cation, intended for ages 6-12. It was hypothesized that probe questions would be 
more effective for cognitive debriefing subjects aged 6-12. Subjects were asked how 
they would respond to the questionnaire in hypothetical conditions to demonstrate 
comprehensibility of the translated text. The second questionnaire contained visual 
analog scales (VAS) to assess pain for those aged 13-18. It was hypothesized that 
paraphrasing without supplementary probes, as used for adult subjects, would suf-
ficiently determine comprehensibility for this age group. Results: The palatability 
assessment was debriefed on 55 subjects with an average age of 9, and a standard 
deviation of 1.9. According to the results, the subjects showed probes were deemed 
to be a success with the younger sample, as they demonstrated their ability to under-
stand how to respond to the questionnaire. The pain VAS scales were debriefed on 50 
subjects with an average age of 15 and a standard deviation of 1.4. Results indicated 
that probes were not necessary if the nature of the questionnaire did not warrant 
them for subjects of any age. Paraphrasing definitively demonstrated comprehension 
by subjects aged 13-18. ConClusions: The results of cognitive debriefing data in 
this study show that probing is a viable method for cognitive debriefing of translated 
COAs with subjects aged 6-12 years old. For questionnaires intended for a population 
for 13-18 years of age, paraphrasing should sufficiently determine comprehension, 
as was demonstrated in this study, the same method that is used for adult subjects.
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Disease state anD MeasuReMent tyPe
Popelar B., Walters T., Zagadailov E.A., Houle C., Duhig A.
Xcenda, Palm Harbor, FL, USA
objeCtives: Productivity outcomes are of interest because they describe the con-
sequence of disease in the workplace and impact on productivity. We conducted 
an analysis of work productivity (WP) endpoints in clinical studies. Methods: 
A keyword search was conducted on Clinicaltrials.gov for “work productivity” to 
identify relevant studies. Trials with terminated, withdrawn, or suspended sta-
tus, those with non-drug interventions, and those without WP endpoints were 
excluded from analysis. A total of 170 studies were included (113 interventional 
and 57 observational studies). Results: Of the 170 studies included, 44% were 
performed outside of the US, 31% were multinational studies including the US, 
and 25% were conducted exclusively in the US. The most common therapeutic 
categories investigated were autoimmune diseases (37%), neurology (14%), and 
psychiatry (9%). Most studies (84%) were sponsored by pharmaceutical manu-
facturers, with 11% sponsored by other institutions, or a combination of both 
(6%). The majority of trials investigated WP as a secondary measure (89%), with 
several, primarily observational studies, reporting WP as a primary outcome (11%). 
Survey instruments were utilized most commonly, representing 82% of studies, 
while 9% of studies evaluated WP based on time missed from work. Some studies 
utilized multiple measures. Generic instruments, such as the Work Productivity 
and Activity Impairment Questionnaire (WPAI), were used in 54% of studies, while 
29% used disease-specific measures. In some cases (15%) a specific tool or instru-
ment for WP was not identified. Most trials (93%) included other patient-reported 
endpoints, in addition to WP. ConClusions: WP endpoints were most commonly 
investigated in manufacturer-sponsored trials as secondary outcomes to demon-
strate patient benefit in therapeutic areas where more concrete clinical outcomes 
are limited. Generic instruments are heavily utilized, with approximately one-third 
of studies utilizing disease specific measures.
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RevieW of caRegiveR BuRDen scales foR Patients With visual 
iMPaiReMent in JaPan
Narimatsu A., Ishii K., Adachi K.
Bayer Yakuhin Ltd., Tokyo, Japan
objeCtives: Among the societal costs of visual impairment in Japan, cost of both 
unpaid and paid home care for people with visual impairment has been estimated 
as a substantial component of indirect cost. However, the degree of burden among 
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receive financial support from industry performed better across our assessment 
criteria. We did not find substantial differences between NMAs published before 
January 1st, 2013, with studies published after that date. ConClusions: There 
is substantial variation in the NMA literature. Consensus among NMA guidelines 
is required to improve methodological quality, consistency, and transparency of 
study conduct and reporting.
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aPPlication of DiffeRence-in-DiffeRence MethoDology in 
coMPaRative effectiveness ReseaRch With unBalanceD gRouPs
Li Y.1, Zhou H.2, Ko J.J.1, Hawker K.1, Nazareth T.1, Arcona S.1, Sasane R.1
1Novartis Pharmaceuticals, East Hanover, NJ, USA, 2KmK Consulting Inc. for Novartis 
Pharmceuticals, Florham Park, NJ, USA
objeCtives: Propensity score matching (PSM) and Inverse Probability of Treatment 
Weighting (IPTW) are analytical methods used in comparative effective research 
(CER) to establish comparison groups. However, these methods may not be appli-
cable in studies with small sample sizes and unbalanced comparison groups. 
In such cases, where there is an unbalanced design due to unmeasured factors, 
difference-in-difference (DD) can be applied to estimate treatment effects. This 
research aims to apply DD to a small sample of multiple sclerosis (MS) patients with 
unbalanced comparison groups. Methods: A retrospective study was conducted 
using MarketScan Commercial Claims and Encounters and Medicare Supplemental 
and Coordination of Benefits Databases to compare MS patients who switched from 
glatiramer acetate (GA) to fingolimod (FTY) with another group maintaining con-
tinuous use of GA. IPTW and DD were applied to balance the comparison groups; 
PSM could not be implemented due to imbalance between groups. Using DD, the 
treatment effect (i.e. % of patients with relapse) was measured in the 1-year baseline 
period and the 1-year follow-up period as: (difference in relapses in the GA--> FTY 
group) minus (difference in relapses in the GA-only group). Results: IPTW was first 
employed to balance the two groups (GA--> FTY [n= 363]; GA-only [6,416]). Despite 
implementation of IPTW, the comparison groups could not be balanced on multiple 
factors such as patient demographics and clinical characteristics; therefore, DD was 
utilized. In the DD analysis, the % of patients with relapse in the GA--> FTY group 
in the baseline and follow-up periods were 30% and 13.8%, respectively (D= 16.2%); 
in the GA-only group, the % of patients with relapse in the baseline and follow-up 
periods were 14% and 11.5%, respectively (D= 2.5%). The estimated reduction of MS 
relapse rate from FTY was 13.7% (DD= 16.2%-2.5%). ConClusions: DD is an effec-
tive methodology which allows for estimating treatment effects from populations 
with unbalanced comparison groups.
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loW-MoleculaR-Weight hePaRin tReatMent of DeeP-vein thRoMBosis: 
a netWoRk Meta-analysis
Diaz J.P.1, Soto Molina H.2, Marquez M.3, Escobar Juárez Y.2
1Universidad Nacional Autonoma de Mexico, México D.F., Mexico, 2HS Estudios 
FarmacoeconÃ³micos, Mexico City, Mexico, 3Universidad Autonoma Metropolitana, México D.F., 
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objeCtives: It is estimated that up to 400,000 persons in Mexico are hospital-
ized yearly for deep-vein thrombosis (DVT). DVT is the presence of a blood clot 
(thrombus) in the deep veins of the body. The main objective was to indirectly 
compare the use of tinzaparin, nadroparin and enoxaparin in terms of safety and 
efficacy for the treatment of deep-vein thrombosis using a network meta-analysis 
(NMA). Methods: To identify suitable studies for a systematic review of treat-
ment of DVT (submitted for abstract), the following databases were searched: 
MEDLINE, Pubmed, EMBASE, CENTRAL (all via The Cochrane Library), Imbiomed, 
HTA, for relevant studies recorded between April 1994 to April 2014. Only ran-
domised controlled trials assessing patients with DVT were included. Studies 
had to report the proportion of patients having recurrence of DVT (efficacy) and 
the proportion of patients having major bleeding (safety). Titles and abstracts 
were screened, data were extracted and risk of bias assessment was undertaken. 
. Bayesian NMA was used to compare the different interventions. Results: Four 
studies, assessing four low molecular weight heparins (LMWH), were judged to be 
sufficiently comparable for inclusion in the NMA. For the proportion of patients 
having recurrence of DVT or major bleeding, enoxaparin 1 mg/kg twice daily, tin-
zaparin 175 IU/kg once daily and nadroparin 100 IU/kg twice daily had a higher 
probability of being more effective and safe than unfractioned heparin. None of 
the LMWHs demonstrated a signiﬁcant superiority over each other in terms of 
efficacy and safety; therefore, the group of LMWHs is suitable for a further cost 
minimization analysis and reference price implementation. ConClusions: We 
found no evidence of differences between tinzaparin, nadroparin and enoxaparin 
for recurrence of DVT and major bleeding. Tinzaparin may be preferred by clini-
cians because it is always given once daily.
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alteRnative Weighting aPPRoaches foR Matching aDJusteD inDiRect 
coMPaRisons (Maic)
Belger M.1, Brnabic A.2, Kadziola Z.3, Petto H.3, Faries D.4
1Eli Lilly and Company (Lilly UK), Surrey, UK, 2Eli Lilly, Sydney, Australia, 3Eli Lilly Regional 
Operations GmbH, Vienna, Austria, 4Eli Lilly, Indianapolis, IN, USA
objeCtives: The use of indirect comparisons (IC) is now an integral part of the 
Health Technology Assessment (HTA). When new interventions are assessed, 
Individual patient data (IPD), if available, can be used for comparison with pub-
lished aggregated (AGR) data. Methods exist to assess heterogeneity and incon-
sistency of IC; however in the absence of sufficient studies, IC may be required 
where differences may exist between inclusion/exclusion criteria, definition of 
outcomes and patient characteristics. Signorovitch (2010) has proposed the use 
of MAIC when IPD is available and provided various methods for matching the 
IPD to the AGR study. Methods: Through simulations we assessed different 
approaches to weight calculations, including weighting as originally proposed 
translated into 17 Asiatic languages (Chinese for China, Hong Kong, Singapore 
and Taiwan, Korean, Bengali, Gujarati, Hindi, Kannada, Malayalam, Marathi, 
Punjabi, Telugu, Urdu, Tamil for India and Singapore, and Malay for Singapore). 
The objective of this study was to identify the main translation challenges, and 
which items needed the most references to conceptual definitions. Methods: In 
each country, the linguistic validation was conducted with the author of the IBS-
QOL, using either the standard forward/backward methodology or the adjusted 
process with reviews by the author, a clinician, and cognitive interviews with 12 
patients. The basis for discussion was the list of concepts (LOC) elaborated with 
the author. For each country, the history grid of the translation process was ana-
lyzed. References/reminders of the LOC and author’s interventions were counted for 
each item across countries. Results: Eleven items were found challenging (items 
2,3,4,7,9,16,18,25,28,31,32). Four of them needed the most to refer to the LOC, i.e., 
item 3 “I am bothered by how much time I spend on the toilet” (100% of the coun-
tries); item 18 “I feel I get less done…” (53%); item 25 “I feel sluggish…” (76%); and 
item 31 “I worry about losing control of my bowels” (59%). For instance, the main 
difficulties with item 3 were conceptual (“on the toilet” not to be confused with “in 
the toilet”), and cultural (e.g., lack of toilets in India, or people squatting, not sitting). 
Examples of challenges will be provided. ConClusions: The development of the 
LOC with the author proved to be critical to the translation process and enabled the 
conceptual harmonization of the translations.
ReseaRch on MethoDs – statistical Methods
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evaluation of Matching-aDJusteD inDiRect coMPaRison iMPleMenteD 
By a ResaMPling MethoD
Wang J.1, Odom D.2, Chirila C.1, Zheng Q.1
1RTI-Health Solutions, Research Triangle Park, NC, USA, 2RTI Health Solutions, Research Triangle 
Park, NC, USA
objeCtives: Matching-adjusted indirect comparison (MAIC) has been proposed as 
a new tool when conducting indirect treatment comparisons in the situation where 
individual-level data are available from one study, but only summary data are avail-
able from another study. This study evaluated the performance of the MAIC method 
proposed by Malangone and Sherman (2011) which is implemented by a resampling 
(bootstrapping) technique. Methods: Two patient-level data sets, similar to two 
clinical trials, were generated: the first with treatments A and placebo, and the 
second with treatments B and placebo. Other variables included in both data sets 
were survival time, censoring indicator, and two baseline categorical variables. In 
both data sets, interactions between baseline characteristics and treatments were 
incorporated such that differential treatment effects across baseline strata were 
present. The SAS programs illustrated in Malangone and Sherman were adopted for 
the MAIC analysis. First, MAIC was applied to a situation in which only summary 
data were available from the first data set and individual-level data were available 
from the second data set. Subsequently, the roles of two data sets were switched 
and the MAIC analysis was applied once again. Results: Using MAIC, when the 
first data set provided summary statistics, the hazard ratio (HR) (95% confidence 
interval [CI]) for A versus placebo was 0.283 (0.246-0.325); the HR (95% CI) for B ver-
sus placebo was 0.586 (0.466, 0.740). When the second data set provided summary 
data, the HR (95% CI) for A versus placebo was 0.489 (0.390-0.612) and for B versus 
placebo was 0.237 (0.205-0.273). The two comparisons produced opposite significant 
inferences. ConClusions: The method proposed by Malangone and Sherman is 
an interesting addition to the MAIC field, but results could be misleading under 
some circumstances. Therefore, the conditions under which this method is suitable 
should be explored further.
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objeCtives: To evaluate the methodological quality of published network meta-
analyses (NMA). Methods: We performed a systematic review of the NMA lit-
erature (through July 2014). For NMAs including pharmaceuticals we assessed 
general study characteristics, study reproducibility and transparency, methods, 
and reporting of findings. We compared NMAs published in higher impact factor 
journals with those published in lower impact factor journals, NMAs published 
before January 1st, 2013, with those published after that date, and studies receiv-
ing financial support from industry with those receiving financial support from 
non-profit institutions or that did not receive support. Results: The systematic 
literature search identified 318 NMAs meeting our inclusion criteria. Forty-eight 
percent of NMAs were published after January 1st 2013, and the majority received 
financial support from non-profit institutions or did not receive support (68%). 
We found notable inconsistencies among NMAs. Eighty percent reported search 
terms, 65% presented sufficient data to reproduce the analysis, 90% the study 
characteristics of included clinical trials, and 61% the network diagram. Seventy 
percent reported a risk of bias assessment of included clinical trials, 56% a sensi-
tivity analysis, and 40% an assessment of model fit. Among NMAs with a closed 
loop, 69% assessed the consistency of direct and indirect evidence. Sixty-four 
percent of NMAs presented the complete matrix of head-to-head treatment com-
parisons. For Bayesian NMAs, 41% reported the probability of each treatment being 
best, 31% reported efficacy ranking, and 16% reported or referenced the model 
code. NMAs published in higher impact factors journals and those that did not 
